文献速递心外重症与机械循环支持

主动脉内球囊反搏治疗在慢性心力衰竭合并心源性休克患者中的临床与血流动力学效应

Clinical and hemodynamic effects of intra-aortic balloon pump therapy in chronic heart failure patients with cardiogenic shock.
PubMed 文献 · J Heart Lung Transplant · 2018-03-20

该研究回顾性分析了2011至2016年在本机构接受主动脉内球囊反搏(IABP)植入的132例慢性心力衰竭急性失代偿合并心源性休克患者。30天生存率为84.1%,78.0%的患者成功桥接至心脏替代治疗或出院。多变量分析显示缺血性心肌病(OR 3.24)和肺动脉搏动指数(PAPi)<2.0(OR 5.04)是IABP治疗中临床恶化的预测因素。

要点

  • 慢性心衰合并心源性休克患者使用IABP后30天生存率为84.1%。
  • 78.0%的患者成功桥接至心脏替代治疗或出院,无需升级设备支持。
  • 缺血性心肌病和PAPi<2.0是IABP治疗中临床恶化的预测因素。

核心结论

  • 在慢性心力衰竭急性失代偿患者中,IABP的总体结局令人鼓舞,IABP是慢性心力衰竭合并心源性休克患者合理的一线设备。
  • 基线右心室功能(以PAPi衡量)是该人群IABP结局的主要预测因素。

研究设计与样本

  • 回顾性研究,纳入2011至2016年在本机构接受IABP植入的132例慢性心力衰竭急性失代偿合并心源性休克患者。

主要发现

  • 总体30天生存率为84.1%。
  • 78.0%的患者成功桥接至心脏替代治疗或出院,无需升级设备支持。
  • IABP支持期间并发症发生率为2.3%。
  • 多变量分析显示,缺血性心肌病(OR 3.24,95%CI 1.16至9.06;p=0.03)和PAPi<2.0(OR 5.04,95%CI 1.86至13.63;p=0.001)是IABP治疗中临床恶化的预测因素。

关键数值与推荐

  • 心源性休克定义为心脏指数<2.2升/分/平方米,且收缩压<90毫米汞柱或需要使用血管活性药物维持该水平。
  • IABP治疗中临床恶化定义为仅用IABP无法桥接至药物治疗出院或持久心脏替代治疗(持久左心室辅助装置或心脏移植)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of the intra-aortic balloon pump (IABP) in acute decompensated heart failure (HF) with cardiogenic shock (CS) is largely undefined. In this study we sought to assess the hemodynamic and clinical response to IABP in chronic HF patients with CS and identify predictors of response to this device. METHODS: We retrospectively reviewed all patients undergoing IABP implantation from 2011 to 2016 at our institution to identify chronic HF patients with acute decompensation and CS (cardiac index <2.2 liters/min/m2 and systolic blood pressure <90 mm Hg or need for vasoactive medications to maintain this level). Clinical deterioration on IABP was defined as failure to bridge to either discharge on medical therapy or durable heart replacement therapy (HRT; durable left ventricular assist device or heart transplant) with IABP alone. RESULTS: We identified 132 chronic HF patients with IABP placed after decompensation with hemodynamic evidence of CS. Overall 30-day survival was 84.1%, and 78.0% of patients were successfully bridged to HRT or discharge without need for escalation of device support. The complication rate during IABP support was 2.3%. Multivariable analysis identified ischemic cardiomyopathy (odds ratio [OR] 3.24, 95% confidence interval [CI] 1.16 to 9.06; p = 0.03) and pulmonary artery pulsatility index (PAPi) <2.0 (OR 5.04, 95% CI 1.86 to 13.63; p = 0.001) as predictors of clinical deterioration on IABP. CONCLUSIONS: Overall outcomes with IABP in acute decompensated chronic HF patients are encouraging, and IABP is a reasonable first-line device for chronic HF patients with CS. Baseline right ventricular function, as measured by PAPi, is a major predictor of outcomes with IABP in this population.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Fried JA, Nair A, Takeda K, et al. Clinical and hemodynamic effects of intra-aortic balloon pump therapy in chronic heart failure patients with cardiogenic shock. J Heart Lung Transplant. 2018. PMID: 29678608. doi:10.1016/j.healun.2018.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。